Aldeyra Therapeutics (ALDX) Stock Forecast & Price Target

Aldeyra Therapeutics is viewed favorably because Reproxalap has produced compelling late-stage data across nine adequate and well-controlled clinical trials, with five meeting all multiplicity-controlled primary endpoints and several others showing numerical benefit, supporting the view that the asset’s efficacy signal is durable. Its lead programs in dry eye disease and allergic conjunctivitis address large, underserved markets, and the company’s RASP platform creates a first-mover advantage with additional candidates across retinal, autoimmune, and cancer-related diseases. Despite repeated FDA setbacks, the planned Formal Dispute Resolution Request to the Office of New Drugs suggests management believes the totality of evidence is strong enough to merit a new review, preserving meaningful regulatory upside.

Aldeyra Therapeutics is facing a deeply negative investment case because reproxalap has repeatedly failed to clear the FDA’s efficacy standard, culminating in another CRL that says the totality of clinical evidence does not support effectiveness. The regulatory path has been increasingly fragile, with the April 2, 2025 PDUFA ending in a CRL, a June 2025 resubmission accepted for December 16, 2025, then extended to March 16, 2026 after the FDA requested the field-trial report, signaling persistent uncertainty and concern over inconsistent study results. Despite one chamber trial meeting its endpoint with ocular discomfort reduction (P=0.002), the broader data package appears methodologically challenged, leaving the company’s lead program and near-term commercialization prospects highly impaired.